Amgen inherits a higher proof bar after rival trial outcome
Amgen is facing a tougher burden of proof as its shares stood at $437.23, following Novartis’s Phase 3 pelacarsen trial results that lowered Lp(a) but failed to cut major cardiovascular events.
23. Novartis's pelacarsen successfully lowered lipoprotein(a), or Lp(a), but did not cut major cardiovascular events in a Phase 3 trial, acco…